uber blondy

If two people are meant to be together, eventually they'll find their way back.

[uber blondy @uberblondy]

Sometimes you just have to accept that some people can only be in your heart, not in your life.

[Bullish @bullishbruk]

Let us never forget: ANKTIVA is the ONLY drug that has fully cleared the spike protein — completely. Dr. Patrick Soon-Shiong offered it to the FDA for FREE, and they refused.
Think about that. Lives on the line, a proven solution on the table, and bureaucracy said no.
This is exactly why we fight for faster access, real FDA reform, and putting patients before politics. ANKTIVA Army — keep shining the light. @LoriMills4CA42 @DrPatrick

[uber blondy @uberblondy]

@barak_miles @bullishbruk If you have invested that much money you should have gone and testify. I believe she did grate and better than those speaking from script

[uber blondy @uberblondy]

@kacdnp91 @bullishbruk That just confirmed How creepy low life you are and by the way the way people respond to your post I think you bought the followers they are bots following you no real people will follow your creepy ass

[uber blondy @uberblondy]

@kacdnp91 @bullishbruk You just puke shit out of your big mouth is that it.

[Bullish @bullishbruk]

$IBRX @kacdnp91 Warning: Avoid “Kelly DNP Functional/Integrative Medicine” (@kacdnnp91)
This account promotes “functional/integrative” treatments, supplements, and protocols that are not FDA-approved for the conditions claimed.
Key concerns:
• Treatments often lack strong clinical evidence and can delay proven care, cause harm, or waste money.
• She is a DNP (nurse practitioner), not a medical doctor.
• Heavy “rebel vs. tyranny” messaging and anti-mainstream narratives are common red flags in unproven alternative health circles.
Advice: Consult licensed physicians and stick to evidence-based, FDA-approved treatments. Always verify claims with reliable medical sources before trying anything promoted as “healing” outside standard medicine.
Protect your health — prioritize science over emotional appeals. $IBRX

[uber blondy @uberblondy]

@FDAOncology I want to know exactly who the ANKTIVA reviewer is. My father needs effective treatment now, not in another 7 months. data shows ANKTIVA works better than the option that was just approved. Patients shouldn’t have to wait this long for a superior therapy. I expect an answer now!

[uber blondy @uberblondy]

Please @FDAOncology, approve this now. Seven more months won’t teach you anything new — you already have the data. Delaying only harms patients by withholding a therapy they need immediately. @SenRonJohnson @Jim_Jordan @RFKJrHealthSec

[Bullish @bullishbruk]

Subject: Urgent Demand: Approve ANKTIVA + BCG for Papillary-Only NMIBC NOW – Patients Cannot Wait Until January 2027
Dear FDA @FDAOncology Leadership, Oncology Center of Excellence, and Review Team:
As a patient advocate, I issue this urgent plea and formal demand for immediate approval of the sBLA expanding ANKTIVA (nogapendekin alfa inbakicept-pmln) + BCG to BCG-unresponsive papillary disease without CIS. The January 6, 2027 PDUFA date is unacceptable. Patients are progressing and suffering today.
Papillary and CIS Are Biologically the Same Disease
At the FDA’s own workshop on May 18, 2026, the majority of panelists and clinicians confirmed that papillary disease and CIS arise from the same cancer clone, are biologically the same, and are treated identically in real-world practice. This directly supports expanding the existing approval for CIS ± papillary to papillary-only disease.
80,000 Patients in Crisis Cannot Wait 7+ Months
Papillary disease comprises ~85% of NMIBC cases. Tens of thousands of BCG-unresponsive patients face repeated recurrences, painful procedures, and high risk of progression to muscle-invasive cancer. Many are elderly or frail and cannot safely undergo radical cystectomy. With no approved bladder-sparing options, they endure preventable suffering, bladder loss, and fear while ANKTIVA + BCG has already demonstrated durable responses and high cystectomy-free survival in papillary cohorts.
These patients need ANKTIVA now.
Demand: Approve ANKTIVA for papillary-only BCG-unresponsive NMIBC immediately. Align with your workshop consensus and put desperate patients first. Delay is no longer ethical.
Sincerely,
Bullish
Patient Advocate
@WSJopinion @SenRonJohnson @SecKennedy @DrPatrick $IBRX

[uber blondy @uberblondy]

@ProfCMaxi @DrPatrick @ImmunityBio To be honest it should be approve now not wait 7more month while patients are dying

[Dr. Pat Soon-Shiong @DrPatrick]

Thanks Ashish @UroDocAsh. Your book entitled, "Bladder Cancer: A Practical Guide" says it all. Together we face patients on a day-to-day level in which we have to make decisions in the best interest of the patient with nothing else considered. I was so grateful for you to have shared with me your views on whether CIS and papillary from a clinical perspective was the same disease and also how you treat patients who have failed all BCG and have papillary disease and face losing their bladder to a life-changing operation of cystectomy.

I was blown away at this year's #AUA2026 when a researcher presented a slide showing that the morbidity and mortality of a cystectomy exceeds even that of a Whipple in which the pancreas, gallbladder portion of the stomach and spleen are all removed. That blew my mind especially since there is an option to save the bladder.

I am posting the segment of our long conversation relating to your views of whether CIS and high grade papillary are treated clinically as the same disease. I was glad to hear the next day at the FDA workshop that your fellow expert colleagues completely agreed with this sentiment that you expressed in our conversation.

[Bullish @bullishbruk]

Subject: Urgent Demand: Approve ANKTIVA + BCG for Papillary-Only NMIBC NOW – Patients Cannot Wait Until January 2027
Dear FDA @FDAOncology Leadership, Oncology Center of Excellence, and Review Team:
As a patient advocate, I issue this urgent plea and formal demand for immediate approval of the sBLA expanding ANKTIVA (nogapendekin alfa inbakicept-pmln) + BCG to BCG-unresponsive papillary disease without CIS. The January 6, 2027 PDUFA date is unacceptable. Patients are progressing and suffering today.
Papillary and CIS Are Biologically the Same Disease
At the FDA’s own workshop on May 18, 2026, the majority of panelists and clinicians confirmed that papillary disease and CIS arise from the same cancer clone, are biologically the same, and are treated identically in real-world practice. This directly supports expanding the existing approval for CIS ± papillary to papillary-only disease.
80,000 Patients in Crisis Cannot Wait 7+ Months
Papillary disease comprises ~85% of NMIBC cases. Tens of thousands of BCG-unresponsive patients face repeated recurrences, painful procedures, and high risk of progression to muscle-invasive cancer. Many are elderly or frail and cannot safely undergo radical cystectomy. With no approved bladder-sparing options, they endure preventable suffering, bladder loss, and fear while ANKTIVA + BCG has already demonstrated durable responses and high cystectomy-free survival in papillary cohorts.
These patients need ANKTIVA now.
Demand: Approve ANKTIVA for papillary-only BCG-unresponsive NMIBC immediately. Align with your workshop consensus and put desperate patients first. Delay is no longer ethical.
Sincerely,
Bullish
Patient Advocate
@WSJopinion @SenRonJohnson @SecKennedy @DrPatrick $IBRX

[uber blondy @uberblondy]

@bullishbruk @houmanhemmati I agree he is a good looking guy

[Bullish @bullishbruk]

Please join me endorsing Dr. Houman D. Hemmati, MD, PhD, the perfect choice to replace Dr. Makary as FDA Commissioner.

UCLA MD, Caltech PhD, Johns Hopkins-trained ophthalmologist, Harvard/MIT fellow. Stem cell pioneer, drug delivery inventor, biotech CMO with multiple approved therapies.
He’ll slash bureaucracy, accelerate lifesaving approvals, and restore trust — without compromising safety.
America needs bold, evidence-based leadership.
We strongly endorse Dr. Houman Hemmati for FDA Commissioner. @realDonaldTrump
@SenRonJohnson @SecKennedy $IBRX

[Bullish @bullishbruk]

Everyone I spoken with hope @houmanhemmati will be the next @US_FDA commissioner @SenRonJohnson @SecKennedy @POTUS @realDonaldTrump $IBRX

[uber blondy @uberblondy]

@oshea9_harry @DrPatrick Is it? Where is the link?

[uber blondy @uberblondy]

@nypost He needs to approve ANKTIVA for lumphopenia

[bluefinsashimi @bluefinsashimi]

$IBRX FDA decision tomorrow? Earnings on Monday? AUA data May 15-18. CEO tweeted "Global expansion. Unstoppable." and flew to Lisbon -- EU deal looks imminent. Three converging catalysts in 10 days on a stock with 44.2M Q1 revenue, +168% YoY, 380M cash [idiotic short ratio]. Long $IBRX. NFA. #Anktiva #BioShield IL-15

[uber blondy @uberblondy]

$IBRX “the elephant in the room” @bullishbruk here is your answer to political hit job by leftists with in the FDA against @DrPatrick @DrMakaryFDA

[Rick Santorum @RickSantorum]

I supported his nomination because he spoke truth during COVID. He immediately fired the best leaders at the FDA, replaced them with anti-Trump leftists who hollowed out FDA, harmed patients, stifled innovation & drove bio-tech to China then lied about it. https://t.co/3ZrqCVuuPm

[Neil Stone @DrNeilStone]

Aaron Siri is an anti vaccine lawyer

He stands to make millions and millions of dollars suing vaccine companies

That's his motivation

[uber blondy @uberblondy]

@LoriMills4CA42 @filipandanielma @lafemme_nikkita @FDA Lori, you are my Shero!